Clinical trial
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally…
NCT00005961 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005961 |
|---|---|
| Title | O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma |
| Official title | A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | O6-benzylguanine, carmustine |
| Enrollment | 40 |
| Start date | Jun 1, 2000 |
| Primary completion | Dec 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: